Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 1, 2014, Pages

  Tarasov, Kirill ^a,c   Ekroos, Kim ^a   Suoniemi, Matti ^a   Kauhanen, Dimple ^a   Sylvänne, Tuulia ^a   Hurme, Reini ^a   Gouni Berthold, Ioanna ^d   Berthold, Heiner K ^e   Kleber, Marcus E ^e   Laaksonen, Reijo ^a,b,c   März, Winfried ^f,g,h  

^a Zora Biosciences Oy   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF COLOGNE   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g SYNLAB ACADEMY   (Germany)

^h MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; EZETIMIBE; GLYCOSPHINGOLIPID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENETIC DISORDER; HEART INFARCTION; HETEROZYGOSITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID ANALYSIS; LIPID BLOOD LEVEL; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OUTCOME ASSESSMENT; PCSK9 GENE; PLESIOMORPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SIGNAL TRANSDUCTION;

AGED; AZETIDINES; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; MACROMOLECULAR SUBSTANCES; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SERINE ENDOPEPTIDASES; SIMVASTATIN;

EID: 84892151115     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2559     Document Type: Article

References (28)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123:e18-e209.
2. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136 905 hospitalizations in Get With The Guidelines. Am Heart J. 2009;157:111-117.e112.
3. Harkewicz R, Dennis EA. Applications of mass spectrometry to lipids and membranes. Annu Rev Biochem. 2011;80:301-325.
4. van Meer G. Cellular lipidomics. EMBO J. 2005;24:3159-3165.
5. Stubiger G, Aldover-Macasaet E, Bicker W, et al. Targeted profiling of atherogenic phospholipids in human plasma and lipoproteins of hyperlipidemic patients using MALDI-QIT-TOF-MS/MS. Atherosclerosis. 2012;224:177-186.
6. Stegemann C, Drozdov I, Shalhoub J, et al. Comparative lipidomics profiling of human atherosclerotic plaques. Circulation Cardiovasc Genet. 2011;4:232-242.
7. Meikle PJ, Wong G, Tsorotes D, et al. Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscleros Thromb Vasc Biol. 2011;31:2723-2732.
8. Winkelmann BR, Marz W, Boehm BO, et al. Rationale and design of the LURIC study- A resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics. 2001;2:S1-S73.
9. Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, Marz W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J. 2010;31:1237-1247.
10. Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, Gouni- Berthold I. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur Heart J. 2010;31:1633-1639.
11. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.
12. Ekroos K, Chernushevich IV, Simons K, Shevchenko A. Quantitative profiling of phospholipids by multiple precursor ion scanning on a hybrid quadrupole time-of-flight mass spectrometer. Anal Chem. 2002;74:941-949.
13. Merrill AH Jr, Sullards MC, Allegood JC, Kelly S, Wang E. Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods. 2005;36:207-224.
14. Stahlman M, Ejsing CS, Tarasov K, Perman J, Boren J, Ekroos K. High-throughput shotgun lipidomics by quadrupole time-of-flight mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2009;877:2664-2672.
15. Ejsing CS, Duchoslav E, Sampaio J, et al. Automated identification and quantification of glycerophospholipid molecular species by multiple precursor ion scanning. Anal Chem. 2006;78:6202-6214.
16. Jung HR, Sylvanne T, Koistinen KM, Tarasov K, Kauhanen D, Ekroos K. High throughput quantitative molecular lipidomics. Biochim Biophys Acta. 2011;1811(11):925-934.
17. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
18. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
19. Billich A, Baumruker T. Sphingolipid metabolizing enzymes as novel therapeutic targets. Subcell Biochem. 2008;49:487-522.
20. Bismuth J, Lin P, Yao Q, Chen C. Ceramide: a common pathway for atherosclerosis? Atherosclerosis. 2008;196:497-504.
21. Hojjati MR, Li Z, Zhou H, et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem. 2005;280:10284-10289.
22. Chatterjee SB, Dey S, Shi WY, Thomas K, Hutchins GM. Accumulation of glycosphingolipids in human atherosclerotic plaque and unaffected aorta tissues. Glycobiology. 1997;7:57-65.
23. Garner B, Mellor HR, Butters TD, Dwek RA, Platt FM. Modulation of THP-1 macrophage and cholesterol-loaded foam cell apolipoprotein E levels by glycosphingolipids. Biochem Biophys Res Commun. 2002;290:1361-1367.
24. Bietrix F, Lombardo E, van Roomen CP, et al. Inhibition of glycosphingolipid synthesis induces a profound reduction of plasma cholesterol and inhibits atherosclerosis development in A.POE.*3 Leiden and low-density lipoprotein receptor -/- mice. Arteriosclerosis, Thrombos Vasc Biol. 2010;30:931-937.
25. Ye J, DeBose-Boyd RA. Regulation of cholesterol and fatty acid synthesis. Cold Spring Harb Perspect Biol. 2011;3(7).
26. Raghow R, Yellaturu C, Deng X, Park EA, Elam MB. SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends Endocrinol Metab. 2008;19:65-73.
27. Taylor AJ, Villines TC, Stanek EJ. Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe. Eur Heart J. 2012;33:2939-2945.
28. Lansky AJ, Ng VG, Maehara A, et al. Gender and the extent of coronary atherosclerosis, plaque composition, and clinical outcomes in acute coronary syndromes. JACC Cardiovasc Imaging. 2012;5:S62-S72.